Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long ...

Alpharetta, Georgia Wednesday, February 12, 2025, 16:30 Hrs [IST] ...

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

Multiple subcutaneous doses safe and well-tolerated >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes >67% ...

ALPHARETTA, Ga. - Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company with a market capitalization of $85.7 million focused on developing therapies for ocular diseases, has announced ...

Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings ...

Excessive screen time and chronic stress, especially in young people, disrupt circadian rhythms and immune function, ...

BEDFORD, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular”), a biopharmaceutical ...

These results will be shared at the virtual Angiogenesis, Exudation ... treatment or aflibercept and anti-VEGF-C directly to the retina with a single intravitreal injection, aiming to reduce ...

Initial interim 52-week results from Phase 2b Population Extension cohort of PRISM clinical trial to be presented by Dante Pieramici, M.D., a Principal Investigator in PRISM, at Angiogenesis, ...

In their last study, IIT's research group saw for the first time that Ziapin2 also acts in a similar manner on neurons in the inner retina unaffected by degeneration, particularly at the bipolar ...